Lab Anim Res.  2017 Jun;33(2):187-194. 10.5625/lar.2017.33.2.187.

Comparison of therapeutic responses to an anticancer drug in three stocks of ICR mice derived from three different sources

Affiliations
  • 1Department of Biomaterials Science, College of Natural Resources & Life Science/Life and Industry Convergence Research Institute, Pusan National University, Miryang 627-706, Korea. dyhwang@pusan.ac.kr
  • 2Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea.
  • 3College of Veterinary Medicine, Kungpook National University, Daegu, 702-701, Korea.

Abstract

Korl:ICR mice, established by the Korean National Institute of Food and Drug Safety Evaluation (NIFDS), are characterized based on their genetic variation, response to gastric injury, and response to constipation inducers. To compare the inhibitory responses of ICR stocks obtained from three different sources to the anticancer drug cisplatin (Cis), alterations in tumor volume, histopathological structure, and toxicity were examined in Sarcoma 180 tumor-bearing Korl:ICR, A:ICR (USA source), and B:ICR (Japan source) mice treated with low and high concentrations of Cis (L-Cis and H-Cis, respectively). Tumor size and volume were lower in H-Cis-treated mice than in L-Cis-treated mice in all three ICR stocks with no significant differences among stocks. There was a significant enhancement of the necrotizing areas in the histological structures in the L-Cis- and H-Cis-treated groups relative to that in the untreated group. The necrotizing area changes were similar in the Sarcoma 180 tumor-bearing Korl:ICR, A:ICR, and B:ICR mice. However, there were stock-bases differences in the serum biomarkers for liver and kidney toxic effects. In particular, the levels of AST, ALT and BUN increased differently in the three H-Cis-treated ICR stocks, whereas the levels of ALP and CRE were constant. Taken together, the results of the present study indicate that Korl:ICR, A:ICR, and B:ICR mice have similar overall inhibitory responses following Cis treatment of Sarcoma 180-derived solid tumors, although there were some differences in the magnitude of the toxic effects in the three ICR stocks.

Keyword

Korl:ICR mice; tumor; Sarcoma 180 cell; cisplatin; toxicity

MeSH Terms

Animals
Biomarkers
Cisplatin
Constipation
Genetic Variation
Kidney
Liver
Mice
Mice, Inbred ICR*
Sarcoma
Sarcoma 180
Tumor Burden
Biomarkers
Cisplatin
Full Text Links
  • LAR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr